Novelix Pharmaceuticals share price
BSE: 536565Healthcare ServicesSmall Cap
NOVELIX PHARMACEUTICALS LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2013
Last close ₹61.41up ₹1.38 (2.30%)
Share price at the BSE close on 28 Oct 2026. Previous close ₹60.03.
28 Oct: open ₹60.00, high ₹61.90, low ₹54.00
52-week range of traded prices to 28 Oct 2026
₹47.33Low, 28 Oct 2025₹92.00High, 16 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹175 Cr2,861st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 48.19
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.09
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,054
Results
Standalone, as consolidated accounts are on record for only 5 of the last ten years; ₹ crore.Novelix Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +179.9%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹37 Crup 46.52%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.18 Crup 29.28%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 3.2%
Revenue by quarter
Peak revenue ₹48 Cr, quarter to Dec 2025; lowest ₹3.96 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.0 | 5.3 | 20.9 | 22.4 | 36.4 | 48.4 | 25.2 | 36.9 |
| Net profit | 0.1 | 0.1 | 0.2 | 0.1 | 0.5 | 1.0 | 0.9 | 1.2 |
| Net margin | 3.3% | 2.8% | 0.9% | 0.5% | 1.5% | 2.1% | 3.6% | 3.2% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹132 Crup 330.71%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2.56 Crup 2,925.56%
- Net margin
- 1.9%
Revenue by year
Peak revenue ₹132 Cr, year to Mar 2026; lowest ₹0.99 Cr, year to Mar 2021
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 2 of the 8 years with results on record
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 3 | 4 | 1 | 1 | – | 1 | – | 31 | 132 |
| Net profit | 0 | 0 | 0 | 0 | −3 | – | 0 | – | 0 | 3 |
| Net margin | 4.3% | 5.8% | 7.0% | 9.2% | −330.7% | – | −4.3% | – | 0.3% | 1.9% |
Standalone. Years to March. The latest is shaded. No results on record for the years to Mar 2022 and Mar 2024.
Business segments
One segment, Pharma Business, carries all the revenue in the year to Mar 2026.
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned. Dividend yield is not shown: no dividend in the years on record.Novelix Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 4% of 173 trading days over the last year.
LowestHighest
Its median62.38Industry median32.40
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +109.6% | +1,327.8% | −85.3% | 0.0% |
| 3 years | +83.7% | – | – | 0.0% |
| 5 years | +52.5% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Novelix Pharmaceuticals insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 9 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Novelix Pharmaceuticals competitors and peers
Healthcare Research, Analytics & Technology, 11 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Novelix Pharmaceuticals in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 IndegeneINDGN | 14,433 | 36.00 | 4.60 | +30.4% | −7.9% | 13.9% | 15.6% | 0.38% |
 Suven Life SciencesSUVEN | 7,574 | – | – | +17.3% | – | −100.5% | −63.0% | 0.00% |
 Vimta LabsVIMTALABS | 2,295 | 28.81 | 5.02 | +15.2% | – | 19.1% | 21.4% | 0.39% |
 BilcareBI | 192 | – | 0.97 | −0.9% | – | – | 5.4% | 0.00% |
 Jeevan Scientific TechnologyJSTL | 164 | – | 2.28 | +66.1% | – | – | 8.8% | 0.00% |
 TAKETAKE | 156 | 12.16 | 5.03 | – | −68.2% | 49.8% | −5.6% | 0.00% |
 GlobalSpace Technologies540654 | 82 | – | 1.44 | +37.2% | – | – | 7.5% | 0.00% |
 Adeshwar MeditexADESHWAR | 23 | 18.03 | 0.60 | – | – | 3.4% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Novelix Pharmaceuticals announcements
Oct 2026
2 Oct · Management
1 Oct · Results
1 Oct · Meeting
Sep 2026
30 Sep · Meeting
7 Sep · Meeting
7 Sep · Meeting
Novelix Pharmaceuticals share price by year
Each calendar year to 2025.Novelix Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 62.62 | +159.3% | 66.82 | 24.15 |
| 2024 | 24.15 | +114.7% | 24.15 | 8.10 |
| 2023 | 11.25 | +8.7% | 11.96 | 8.00 |
| 2022 | 10.35 | +54.5% | 10.45 | 7.00 |
| 2021 | 6.70 | +8.4% | 10.62 | 4.28 |
| 2020 | 6.18 | +123.1% | 7.09 | 1.85 |
| 2019 | 2.77 | −60.4% | 7.00 | 2.77 |
| 2018 | 7.00 | −22.2% | 9.56 | 6.89 |
| 2017 | 9.00 | +36.4% | 9.87 | 5.70 |
| 2016 | 6.60 | −14.3% | 9.25 | 5.61 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 17 Jan 2020. 2019 is from its first session, 10 May 2019. The 2018 close is its last trade, on 12 Sep 2018.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 27 Oct 2026 | 59.00 | 60.03 | 56.45 | 60.03 | 59.75 | 1,479 |
| 26 Oct 2026 | 62.00 | 62.00 | 54.00 | 59.20 | 56.99 | 6,780 |
| 23 Oct 2026 | 59.00 | 62.00 | 59.00 | 59.54 | 59.95 | 1,524 |
| 22 Oct 2026 | 60.10 | 62.74 | 60.10 | 62.73 | 62.03 | 1,364 |
| 21 Oct 2026 | 63.98 | 64.00 | 61.01 | 62.74 | 62.62 | 373 |
| 19 Oct 2026 | 63.41 | 64.72 | 57.40 | 64.13 | 63.01 | 1,618 |
| 16 Oct 2026 | 65.85 | 65.85 | 62.20 | 63.41 | 63.41 | 3,858 |
| 15 Oct 2026 | 67.95 | 67.95 | 63.00 | 63.89 | 64.04 | 4,005 |
| 14 Oct 2026 | 69.20 | 69.29 | 62.25 | 65.44 | 64.24 | 5,109 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 536565
- ISIN
- INE314I01036
- Industry
- Healthcare Services
- Website
- novelixpharma.com
- CIN
- L67120TG1994PLC018956
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1994
- Registered office
- 5-8-354/1106, Office no. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad 500001, Telangana
- Share registrar
- Venture Capital & Corporate Investments Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments